

# AUSTRALIAN PRODUCT INFORMATION – TORISEL<sup>®</sup> (TEMSIROLIMUS)

## 1. NAME OF THE MEDICINE

Temsirolimus

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each vial of TORISEL (temsirolimus) concentrate for injection contains 30 mg temsirolimus.

Each vial of diluent contains ethanol absolute 438 mg, macrogol-400 941 mg and polysorbate 80, 880 mg.

### Excipient(s) with known effect:

#### *TORISEL vial:*

ethanol absolute

#### *Diluent vial:*

ethanol absolute

For the full list of excipients, see Section 6.1 List of excipients.

## 3. PHARMACEUTICAL FORM

**Temsirolimus concentrate for injection vial:** Concentrate for injection

**Diluent vial:** Solution for injection

## 4. CLINICAL PARTICULARS

### 4.1 Therapeutic indications

#### **Renal Cell Carcinoma**

TORISEL is indicated for the treatment of advanced renal cell carcinoma.

#### **Mantle Cell Lymphoma**

TORISEL is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

### 4.2 Dose and method of administration

Treatment should continue until the patient is no longer clinically benefiting from therapy or until unacceptable toxicity occurs. No special dosage modification is required for any of the populations that have been studied (e.g. gender, elderly).

## **Renal Cell Carcinoma**

The recommended dose of TORISEL for advanced renal cell carcinoma is 25 mg, infused over a 30-60 minute period once a week.

Management of suspected drug reactions may require temporary interruption and/or dose reduction of TORISEL therapy. If a suspected reaction is not manageable with dose delays, then Temsirolimus Concentrate for Injection may be reduced by 5 mg/week decrements.

## **Mantle Cell Lymphoma**

The recommended dosing regimen of temsirolimus for mantle cell lymphoma is 175 mg, infused over a 30-60 minute period once weekly for 3 weeks followed by weekly doses of 75 mg, infused over a 30-60 minute period.

Management of suspected adverse reactions may require temporary interruption and/or dose reduction of temsirolimus therapy. If a suspected reaction is not manageable with dose delays, then temsirolimus may be reduced as follows - if the reaction occurs during the 175 mg dosing, the 175 mg weekly dose should be reduced to 75 mg weekly. Thereafter, the dose may be reduced by 25 mg/week decrements, to a minimum of 25 mg weekly.

## **Instructions for Intravenous Administration**

TORISEL and diluent must be stored under refrigeration at 2°C - 8°C and protected from light. During handling and preparation of admixtures, TORISEL should be protected from excessive room light and sunlight.

TORISEL and diluent should be inspected visually for particulate matter and discoloration prior to administration. Bags/containers that come in contact with TORISEL must be made of glass, polyolefin, or polyethylene.

**DO NOT USE IF PARTICULATES ARE PRESENT. USE A NEW VIAL.**

## **Premedication**

Patients should receive prophylactic medication of an intravenous antihistamine approximately 30 minutes before the start of each dose of TORISEL infusion. If a hypersensitivity/infusion reaction develops during the TORISEL infusion, the infusion should be stopped.

Upon adequate resolution, and at the discretion of the physician, treatment may be resumed with the administration of an H<sub>1</sub>-receptor antagonist (or equivalent), if not previously administered, and/or an H<sub>2</sub>-receptor antagonist (such as intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. The infusion may then be resumed at a slower rate (up to 60 minutes).

## **Dilution**

Note: For mantle cell lymphoma, multiple vials will be required for each dose over 25 mg. Each vial of TORISEL should be diluted according to the instructions below. The required contents from each vial should be combined in one syringe for injection into 250 mL of 0.9% sodium chloride injection.

The diluted solution (concentrate and diluent) should be inspected visually for particulate matter and discoloration.

In preparing the temsirolimus administration solution, follow this two-step dilution process in an aseptic manner:

**Step 1:** Inject 1.8 mL of supplied diluent into the vial of TORISEL Concentrate for Injection. Mix well by inversion of the vial. One vial of TORISEL Concentrate contains 30 mg of temsirolimus. When the 1.2 mL vial of concentrate is combined with 1.8 mL of diluent, a total volume of 3.0 mL is obtained, and the concentration of temsirolimus is 10 mg/mL.

Allow sufficient time for air bubbles to subside from the TORISEL concentrate-diluent mixture. The resulting solution is clear to slightly turbid, colourless to light-yellow to yellow, essentially free from visual particulates. **Only 2.5 mL of solution, containing 25 mg temsirolimus, should be extracted from the vial.**

The TORISEL concentrate-diluent mixture is chemically stable when stored at controlled room temperature 20°C to 25°C for up to 24 hours. However, to reduce microbiological hazard the mixture should be used as soon as possible after preparation.

**Step 2:** Withdraw the required amount of TORISEL Concentrate for Injection/Diluent mixture from step 1 (10 mg/mL) and inject rapidly into 250 mL of 0.9% sodium chloride injection to ensure adequate mixing. Mix the admixture by inversion of the bag or bottle. Avoid excessive shaking as this may cause foaming.

The final diluted solution in the bag or bottle should be inspected visually for particulate matter.

### **Administration**

Administration of the final diluted infusion solution should be completed within six hours from the time that the concentrate diluent mixture is added to the sodium chloride injection.

The use of an infusion pump is the preferred method of administration to ensure accurate delivery of the drug.

Appropriate administration materials must be composed of glass, polyolefin, or polyethylene to avoid excessive loss of drug and to decrease the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction. The administration materials must consist of non-DEHP non-polyvinyl chloride (PVC) tubing with the appropriate filter. It is important that the recommendations in this section be followed closely.

An in-line polyethersulfone filter with a pore size of not greater than 5 microns is recommended for administration to avoid the possibility of particles bigger than 5 microns being infused. If the administration set available does not have an in-line filter incorporated, a filter should be added at the end of the set (i.e., an end-filter) before the admixture reaches the vein of the patient. Different end-filters can be used ranging in filter pore size from 0.2 microns up to 5 microns. The use of both an in-line and end-filter is not recommended.

TORISEL, when constituted, contains polysorbate 80, which is known to increase the rate of di-(2-ethylhexyl)phthalate (DEHP) extraction from polyvinyl chloride (PVC). This should be considered during the preparation and administration of TORISEL, including storage time elapsed in a PVC container following constitution.

Infusion sets and bags made of soft plastic such as ethylene vinyl acetate should not be used due to the potential to lose drug over time.

It is important that the recommendations in the Section 4.2 Dose and method of administration are followed closely.

### **Use in Patients with Renal Impairment**

Following a 25 mg intravenous dose of [<sup>14</sup>C]-labelled temsirolimus in healthy subjects, renal elimination of total radioactivity was 4.6% of the administered dose. Renal elimination is a minor pathway; therefore, renal impairment is not expected to markedly influence drug exposure, and no dosage adjustment of TORISEL is required in patients with renal impairment. Studies in patients with varying renal impairment have not been conducted.

TORISEL has not been studied in patients undergoing haemodialysis.

### **Use in Patients with Hepatic Impairment**

Temsirolimus is contraindicated in patients with bilirubin >1.5 x ULN due to increased risk of death, including deaths due to progression of underlying cancer (see Section 4.3 Contraindications).

Use caution when treating patients with mild hepatic impairment. Concentrations of temsirolimus and its metabolite sirolimus were increased in patients with elevated AST or bilirubin levels. Assessment of AST and bilirubin levels is recommended before initiation of temsirolimus and periodically thereafter.

### **Use in Children**

The safety and effectiveness of TORISEL in paediatric patients have not been established.

### **Use in Elderly Patients**

No specific dose adjustment is recommended for elderly patients (see Section 4.4 Special warnings and precautions for use - Use in the elderly).

### **Compatibilities, Incompatibilities**

TORISEL Concentrate for Injection should not be added directly to aqueous infusion solutions. Direct addition of TORISEL Concentrate for Injection to aqueous solutions will result in precipitation of drug. Always combine TORISEL Concentrate for Injection with diluent for TORISEL Concentrate for Injection before adding to infusion solutions. It is recommended that TORISEL be administered in 0.9% sodium chloride injection after combining with diluent. The stability of temsirolimus in other infusion solutions has not been evaluated. Addition of other drugs or nutritional agents to admixtures of temsirolimus in sodium chloride injection has not been evaluated and should be avoided. Temsirolimus is degraded by both acids and bases, and thus combinations of temsirolimus with agents capable of modifying solution pH should be avoided.

## **4.3 Contraindications**

TORISEL is contraindicated in patients with a known hypersensitivity to temsirolimus or any component of this formulation.

TORISEL is contraindicated in patients with bilirubin >1.5 x ULN (see Section 4.4 Special warnings and precautions for use - Use in hepatic impairment).

## 4.4 Special warnings and precautions for use

### Hypersensitivity/Infusion Reactions

Hypersensitivity/infusion reactions (including some life-threatening and rare fatal reactions), including but not limited to flushing, chest pain, dyspnoea, hypotension, apnoea, loss of consciousness, hypersensitivity and anaphylaxis, have been associated with the administration of temsirolimus. These reactions can occur very early in the first infusion, but may also occur with subsequent infusions. Patients should be monitored early during the infusion and appropriate supportive care should be available. Temsirolimus infusion should be interrupted in all patients with severe infusion reactions and appropriate medical therapy administered. A benefit-risk assessment should be done prior to the continuation of temsirolimus therapy in patients with severe or life-threatening reactions.

Sirolimus is the major metabolite of temsirolimus; therefore, TORISEL should be administered with caution in patients with a known hypersensitivity to sirolimus.

Because it is recommended that an H<sub>1</sub> antihistamine be administered to patients before the start of the intravenous TORISEL infusion, TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine or patients who cannot receive an antihistamine for other medical reasons.

If a patient develops a hypersensitivity reaction during the TORISEL infusion despite the premedication, the infusion should be stopped and the patient should be observed for at least 30 to 60 minutes (depending on the severity of the reaction). At the discretion of the physician, treatment may be resumed with the administration of an H<sub>1</sub>-receptor antagonist (such as diphenhydramine), if not previously administered, and/or an H<sub>2</sub>-receptor antagonist (such as intravenous ranitidine 50 mg) approximately 30 minutes before restarting the TORISEL infusion. The infusion may then be resumed at a slower rate (up to 60 minutes).

### Hyperglycaemia/Glucose Intolerance

The use of TORISEL in renal cell carcinoma patients was associated with increases in serum glucose. In Study 1, a Phase 3 clinical trial for renal cell carcinoma, 26% of patients reported hyperglycaemia as an adverse event. In Study 3, a Phase 3 clinical trial for mantle cell lymphoma, 11% of patients reported hyperglycaemia as an adverse event. This may result in the need for an increase in the dose of, or initiation of, insulin and/or oral hypoglycaemic agent therapy. Patients should be advised to report excessive thirst or any increase in the volume or frequency of urination.

### Infections

Patients may be immunosuppressed and should be carefully observed for the occurrence of infections, including opportunistic infections. Cases of *Pneumocystis jiroveci* pneumonia (PJP), some with fatal outcomes, have been reported in patients who received temsirolimus, many of whom also received corticosteroids or other immunosuppressive agents. For patients who require concomitant use of corticosteroids or other immunosuppressive agents, prophylaxis of PJP may be considered.

## **Interstitial Lung Disease**

There have been cases of non-specific interstitial pneumonitis, including fatal reports, occurring in patients who received weekly intravenous TORISEL. Some patients were asymptomatic or had minimal symptoms with pneumonitis detected on computed tomography scan or chest radiograph. Others presented with symptoms such as dyspnoea, cough, and fever. Some patients required discontinuation of TORISEL or treatment with corticosteroids and/or antibiotics, while some patients continued treatment without additional intervention.

It is recommended that patients undergo baseline radiographic assessment by lung computed tomography scan or chest radiograph prior to the initiation of temsirolimus therapy. Follow such assessments periodically, even in the absence of clinical respiratory symptoms.

It is recommended that patients be followed closely for occurrence of clinical respiratory symptoms.

If clinically significant respiratory symptoms develop, consider withholding temsirolimus administration until after recovery of symptoms and improvement of radiographic findings related to pneumonitis. Opportunistic infections such as PJP should be considered in the differential diagnosis. Empiric treatment with corticosteroids and/or antibiotics may be considered. For patients who require use of corticosteroids, prophylaxis of PJP may be considered.

## **Hyperlipidaemia**

The use of TORISEL was associated with increases in serum triglycerides and cholesterol. In Study 1, hyperlipidaemia was reported as an adverse event (including elevated triglycerides and/or cholesterol) in 27% of patients. In Study 3, hyperlipaemia was reported as an adverse event in 9.3% of patients. This may require initiation or increase in the dose of lipid-lowering agents. Serum cholesterol and triglycerides should be tested before and during treatment with TORISEL.

## **Bowel Perforation**

Cases of bowel perforation (including fatal outcomes) have occurred in patients who received TORISEL.

## **Wound Healing Complications**

The use of TORISEL has been associated with abnormal wound healing. Therefore, caution should be exercised with the use of TORISEL in the peri-surgical period.

## **Intracerebral Bleeding**

Patients with central nervous system tumours (primary CNS tumours or metastases) and/or receiving anticoagulation therapy may be at an increased risk of developing intracerebral bleeding (including fatal outcomes) while receiving therapy with TORISEL.

## **Renal Failure**

Renal failure (including fatal outcomes) has been observed in patients receiving TORISEL for advanced renal cell cancer and/or with pre-existing renal insufficiency.

## Thrombocytopenia and Neutropenia

Grades 3 and 4 thrombocytopenia and/or neutropenia have been observed in Study 3 (mantle cell lymphoma).

## Cataracts

Cataracts have been observed in some patients who received the combination of TORISEL and IFN-  $\alpha$ .

## Vaccinations

The use of live vaccines should be avoided during treatment with TORISEL. Examples of live vaccines are: measles, mumps, rubella, oral polio, Bacillus Calmette-Guérin (BCG), yellow fever, varicella, and TY21a typhoid vaccines.

## Use in hepatic impairment

TORISEL was evaluated in a dose escalation Phase 1 study in 110 patients with normal or varying degrees of hepatic impairment as defined by AST and bilirubin levels and patients with liver transplant (Table 1). Patients with moderate and severe hepatic impairment had increased rates of adverse events and deaths, including deaths due to progressive disease, during the study.

**TABLE 1 ADVERSE EVENTS IN PATIENTS WITH ADVANCED MALIGNANCIES PLUS NORMAL OR IMPAIRED HEPATIC FUNCTION**

| Hepatic Function       | TORISEL dose range (mg) | Adverse Events Grade $\geq$ 3 n(%)** | Overall Death*** n (%) |
|------------------------|-------------------------|--------------------------------------|------------------------|
| Normal (n=25)          | 25 – 175                | 20 (80.0)                            | 2 (8.0)                |
| Mild (n=39)            | 10 – 25                 | 32 (82.1)                            | 5 (12.8)               |
| Moderate (n=20)        | 10 – 25                 | 19 (95.0)                            | 8 (40.0)               |
| Severe (n=24)          | 7.5 – 15                | 23 (95.8)                            | 13 (54.2)              |
| Liver Transplant (n=2) | 10                      | 1 (50.0)                             | 0 (0)                  |

\* Hepatic Function Groups: normal = bilirubin and AST  $\leq$  ULN; mild = bilirubin  $>1 - 1.5 \times$  ULN or AST  $>$ ULN but bilirubin  $\leq$  ULN; moderate = bilirubin  $> 1.5 - 3 \times$  ULN; severe = bilirubin  $>3 \times$  ULN; liver transplant = any bilirubin and AST.  
\*\* Common Terminology Criteria for Adverse Events, version 3.0, including all causality.  
\*\*\* Includes deaths due to progression of underlying cancer and adverse reactions.

TORISEL is contraindicated in patients with bilirubin  $>1.5 \times$  ULN due to increased risk of death, including deaths due to progression of underlying cancer (see Section 4.3 Contraindications).

Use caution when treating patients with mild hepatic impairment. Concentrations of temsirolimus and its metabolite sirolimus were increased in patients with elevated AST or bilirubin levels. Assessment of AST and bilirubin levels is recommended before initiation with temsirolimus and periodically thereafter.

## Use in renal impairment

See Section 4.2 Dose and method of administration - Use in Patients with Renal Impairment, and Section 4.4 Special warnings and precautions for use - Renal Failure.

### **Use in the elderly**

Based on the results of a Phase 3 study for renal cell carcinoma, elderly patients may be more likely to experience certain adverse reactions, including oedema, diarrhoea, and pneumonia. Based on the results of a Phase 3 study for mantle cell lymphoma, elderly patients may be more likely to experience certain adverse reactions, including anxiety, depression, dyspnoea, leukopenia, myalgia, taste loss, and upper respiratory infection.

Overall survival in a subset of patients 65 years of age or older (n =64) treated with TORISEL was shorter than that observed with patients under 65 years of age and was not significantly different from INF- $\alpha$  (see Section 5.1 Pharmacodynamic properties - Clinical trials). The clinical relevance of this subgroup analysis is unclear.

No specific dose adjustment is recommended for elderly patients.

### **Paediatric use**

The safety and effectiveness of TORISEL in paediatric patients have not been established.

### **Effects on laboratory tests**

Not applicable.

## **4.5 Interactions with other medicines and other forms of interactions**

Temsirolimus and its active metabolite sirolimus are metabolised predominately by CYP3A4/5.

### **Agents Inducing CYP3A Metabolism**

Agents such as carbamazepine, phenytoin, barbiturates, rifabutin, rifampicin, and St. John's Wort are strong inducers of CYP3A4/5 and may decrease composite exposures of the active moieties, temsirolimus and its metabolite, sirolimus. Therefore, concomitant treatment with agents that have CYP3A4/5 induction potential should be avoided. If alternative treatment cannot be administered, a weekly intravenous dose up to 50 mg should be considered. For patients with mantle cell lymphoma, it is recommended that coadministration of CYP3A4/5 inducers should be avoided due to the higher dose of temsirolimus.

Co-administration of TORISEL with rifampin, a potent CYP3A4/5 inducer, had no significant effect on temsirolimus maximum concentration ( $C_{max}$ ) and AUC, after intravenous administration, but decreased sirolimus  $C_{max}$  by 65% and AUC by 56%, and AUC<sub>sum</sub> (composite of temsirolimus AUC plus sirolimus AUC) by 41% compared to TORISEL treatment alone.

### **Agents Inhibiting CYP3A Metabolism**

Agents such as protease inhibitors (such as atazanavir, indinavir nelfinavir, ritonavir and saquinavir), anti-fungals (such as itraconazole and ketoconazole), and macrolide antibiotics (such as clarithromycin and telithromycin) are strong CYP3A4 inhibitors and may increase blood concentrations of the active moieties, temsirolimus and its metabolite, sirolimus. Therefore, concomitant treatment with agents that have CYP3A4 inhibition potential should be avoided. Concomitant treatment with moderate CYP3A4 inhibitors should only be

administered with caution in patients receiving 25 mg and should be avoided in patients receiving temsirolimus doses higher than 25 mg.

Alternative treatments with agents that do not have CYP3A4 inhibition potential should be considered.

Co-administration of TORISEL with ketoconazole, a potent CYP3A4 inhibitor, had no significant effect on temsirolimus  $C_{max}$  or AUC; however, sirolimus AUC increased 3.1-fold, and  $AUC_{sum}$  increased 2.3-fold compared to TORISEL alone. Substances that are potent inhibitors of CYP3A4 activity increase sirolimus blood concentrations.

### **Interactions with Drugs Metabolised by CYP2D6**

In 23 healthy subjects the concentration of desipramine, a CYP2D6 substrate, was unaffected when 25 mg of TORISEL was co-administered. In 36 patients with MCL, including 4 poor metabolisers, the effect of CYP2D6 inhibition after administration of a single dose of 175 mg and 75 mg temsirolimus was investigated. Population PK analysis based on sparse sampling indicated no clinically significant interaction effect on desipramine AUC and  $C_{max}$  in plasma. No clinically significant effect is anticipated when TORISEL is co-administered with agents that are metabolised by CYP2D6.

### **Interactions with Drugs Metabolised by CYP3A4/5**

#### ***Patients with RCC***

The effect of a 25 mg dose of temsirolimus on CYP3A4/5 substrates has not been studied. In vitro studies in human liver microsomes and simulation using physiologically-based PK modelling indicate that the blood concentrations achieved after 25 mg dose of temsirolimus may increase the AUC and  $C_{max}$  of midazolam, a CYP3A4/5 substrate, by 28% and 9% respectively. No clinically significant effect is anticipated when temsirolimus at a dose of 25 mg is co-administered with agents that are metabolised by CYP3A4/5.

#### ***Patients with MCL***

The effect of a 175 mg or 75 mg temsirolimus dose on CYP3A4/5 substrates has not been studied. However, in vitro studies in human liver microsomes and simulations using physiologically-based PK models indicate that the blood concentrations achieved after a 175 mg dose of temsirolimus may increase the AUC and  $C_{max}$  of midazolam by 182% and 40%, respectively. PK modelling at a 75 mg dose of temsirolimus was not studied. Therefore, caution is advised during concomitant administration of TORISEL to patients with MCL with medicinal products that are metabolised predominantly via CYP3A4/5 and that have a narrow therapeutic index.

### **Interactions with Drugs that are P-glycoprotein Substrates**

In an in vitro study, temsirolimus inhibited the transport of digoxin, a P-glycoprotein (P-gp) substrate, with an  $IC_{50}$  value of 2  $\mu$ M. Clinical implications related to concomitant administration of P-gp substrates are not known.

### **Concomitant Use of TORISEL with Sunitinib**

The combination of TORISEL and sunitinib resulted in dose-limiting toxicity. Dose-limiting toxicities (grade 3/4 erythematous maculopapular rash, gout/cellulitis requiring hospitalisation) were observed in two out of three patients treated in the first cohort of a Phase I study at doses

of TORISEL 15 mg intravenous per week and sunitinib 25 mg oral per day (days 1-28 followed by a 2-week rest).

### **Concomitant Use of Angiotensin-Converting Enzyme (ACE) Inhibitors**

Angioneurotic oedema-type reactions (including delayed reactions occurring two months following initiation of therapy) have been observed in some patients who received TORISEL and ACE inhibitors concomitantly.

### **Concomitant Use of ACE Inhibitors and/or Calcium Channel Blockers**

An increased risk of angioedema is possible in patients taking mTOR inhibitors in combination with ramipril and/or amlodipine. Caution should be used when temsirolimus is given concomitantly with an ACE inhibitor (e.g. ramipril) or a calcium channel blocker (e.g. amlodipine).

## **4.6 Fertility, pregnancy and lactation**

### **Effects on fertility**

In male rats, fertility was decreased at doses  $\geq 0.5$  mg/kg/day PO. Exposure (AUC; normalised for the frequency of administration) at this dose was below that expected at the maximum recommended human dose. Fertility was absent at 5 mg/kg/day. These effects on male fertility were accompanied by testicular tubular degeneration, decreased sperm concentration and motility, and decreased reproductive organ weights at dosages  $\geq 0.5$  mg/kg/day.

In female rats given temsirolimus for 2 weeks prior to mating until gestation day 6, there were increased incidences of pre- and post-implantation losses at dosages  $\geq 0.7$  mg/kg/day PO, resulting in decreased numbers of live foetuses which was considerably less than the maximum recommended dose on an AUC basis.

### **Use in pregnancy – Pregnancy Category D**

There are no adequate and well-controlled studies in pregnant women using TORISEL.

In oral developmental toxicity studies in rats, there was increased embryo/foetal mortality and decreased foetal growth at dosages  $\geq 0.45$  mg/kg/day. Exposure at this dose was considerably below that expected at the maximum recommended human dose on an AUC basis.

In oral developmental toxicity studies in rabbits, there was increased embryo/foetal mortality and decreased foetal growth at dosages  $\geq 0.6$  mg/kg/day. Exposure at this dose was considerably below that expected at the maximum recommended human dose on an AUC basis.

Women of childbearing age should use medically acceptable contraception during (and up to 12 weeks after) treatment.

TORISEL should not be used during pregnancy.

If a patient becomes pregnant during treatment with TORISEL, she and her treating physician should have a thorough discussion of the diagnosis, alternative options and the potential risks of TORISEL to the developing foetus.

In addition, men should be adequately counselled prior to starting treatment with TORISEL and need to understand the possible danger of taking a drug whose effects on the foetus or sperm are unknown. Men with partners of childbearing potential should use medically acceptable contraception throughout treatment and are recommended to continue this for 12 weeks after the last dose of TORISEL.

There is no information available for labour and delivery.

### **Use in lactation**

Lactation studies of intravenous TORISEL have not been conducted.

It is not known whether temsirolimus is excreted into human milk. Because many drugs are excreted in human milk, and because the effects of temsirolimus excretion in human milk have not been studied, women should be advised against breast-feeding while receiving TORISEL.

## **4.7 Effects on ability to drive and use machines**

The effects of this medicine on a person's ability to drive and use machines were not assessed as part of its registration.

## **4.8 Adverse effects (undesirable effects)**

The following serious adverse reactions have been associated with TORISEL in clinical trials and are discussed in greater detail in the Section 4.4 Special warnings and precautions for use.

Hypersensitivity/Infusion Reactions

Hepatic Impairment

Hyperglycaemia/Glucose Intolerance

Infections

Interstitial Lung Disease

Hyperlipidaemia

Bowel Perforation

Wound Healing Complications

Thrombocytopenia and Neutropenia

Renal Failure

The most common ( $\geq 30\%$ ) adverse reactions observed with TORISEL are rash, asthenia, mucositis, nausea, oedema, and anorexia. The most common ( $\geq 30\%$ ) laboratory abnormalities observed with TORISEL are anaemia, hyperglycaemia, hyperlipaemia, hypertriglyceridaemia, lymphopenia, elevated alkaline phosphatase, elevated serum creatinine, hypophosphataemia, thrombocytopenia, elevated AST, and leukopenia.

## Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other trials and may not reflect the rates observed in clinical practice.

### Renal Cell Carcinoma

In the Phase 3 randomised, open-label study of interferon alpha (IFN- $\alpha$ ) alone, TORISEL alone, and TORISEL and IFN- $\alpha$ , a total of 616 patients were treated. Two hundred patients received IFN- $\alpha$  weekly, 208 received TORISEL 25 mg weekly, and 208 patients received a combination of TORISEL and IFN- $\alpha$  weekly (see Section 5.1 Pharmacodynamic properties - Clinical trials).

Treatment with the combination of TORISEL 15 mg and IFN- $\alpha$  was associated with an increased incidence of multiple adverse reactions and did not result in a significant increase in overall survival when compared with IFN- $\alpha$  alone.

Table 2 shows the percentage of patients experiencing treatment emergent adverse reactions. Reactions reported in at least 10% of patients who received TORISEL 25 mg alone or IFN- $\alpha$  alone are listed. Table 3 shows the percentage of patients experiencing selected laboratory abnormalities. Data for the same adverse reactions and laboratory abnormalities in the IFN- $\alpha$  alone arm are shown for comparison.

**TABLE 2: ADVERSE REACTIONS REPORTED IN AT LEAST 10% OF PATIENTS WHO RECEIVED 25 IV TORISEL OR IFN-ALPHA IN THE RANDOMISED TRIAL**

| Adverse Reaction                  | TORISEL<br>25 mg<br>n=208 |                         | IFN- $\alpha$<br>n=200  |                         |
|-----------------------------------|---------------------------|-------------------------|-------------------------|-------------------------|
|                                   | All<br>Grades*<br>n (%)   | Grades<br>3&4*<br>n (%) | All<br>Grades*<br>n (%) | Grades<br>3&4*<br>n (%) |
| <b>Any</b>                        | 208 (100)                 | 139 (67)                | 199 (100)               | 155 (78)                |
| <b>General disorders</b>          |                           |                         |                         |                         |
| Asthenia                          | 106 (51)                  | 23 (11)                 | 127 (64)                | 52 (26)                 |
| Oedema <sup>a</sup>               | 73 (35)                   | 7 (3)                   | 21 (11)                 | 1 (1)                   |
| Pain                              | 59 (28)                   | 10 (5)                  | 31 (16)                 | 4 (2)                   |
| Pyrexia                           | 50 (24)                   | 1 (1)                   | 99 (50)                 | 7 (4)                   |
| Weight Loss                       | 39 (19)                   | 3 (1)                   | 50 (25)                 | 4 (2)                   |
| Headache                          | 31 (15)                   | 1 (1)                   | 30 (15)                 | 0 (0)                   |
| Chest Pain                        | 34 (16)                   | 2 (1)                   | 18 (9)                  | 2 (1)                   |
| Chills                            | 17 (8)                    | 1(1)                    | 59 (30)                 | 3 (2)                   |
| <b>Gastrointestinal disorders</b> |                           |                         |                         |                         |
| Mucositis <sup>b</sup>            | 86 (41)                   | 6 (3)                   | 19 (10)                 | 0 (0)                   |
| Anorexia                          | 66 (32)                   | 6 (3)                   | 87 (44)                 | 8 (4)                   |
| Nausea                            | 77 (37)                   | 5 (2)                   | 82 (41)                 | 9 (5)                   |
| Diarrhoea                         | 56 (27)                   | 3 (1)                   | 40 (20)                 | 4 (2)                   |
| Abdominal Pain                    | 44 (21)                   | 9 (4)                   | 34 (17)                 | 3 (2)                   |
| Constipation                      | 42 (20)                   | 0 (0)                   | 36 (18)                 | 1 (1)                   |

| Adverse Reaction                                       | TORISEL        |        | IFN- $\alpha$ |        |
|--|----------------|--------|---------------|--------|
|  | 25 mg<br>n=208 |        | n=200         |        |
| Vomiting   | 40 (19)        | 4 (2)  | 57 (29)       | 5 (3)  |
| <b>Infections</b>                                      |                |        |               |        |
| Infections <sup>c</sup>                                | 42 (20)        | 6 (3)  | 19 (10)       | 4 (2)  |
| Urinary tract infection <sup>d</sup>                   | 31 (15)        | 3 (1)  | 24 (12)       | 3 (2)  |
| Pharyngitis  | 25 (12)        | 0 (0)  | 3 (2)         | 0 (0)  |
| Rhinitis   | 20 (10)        | 0 (0)  | 4 (2)         | 0 (0)  |
| <b>Musculoskeletal and connective tissue disorders</b> |                |        |               |        |
| Back Pain  | 41 (20)        | 6 (3)  | 28 (14)       | 7 (4)  |
| Arthralgia   | 37 (18)        | 2 (1)  | 29 (15)       | 2 (1)  |
| Myalgia  | 16 (8)         | 1 (1)  | 29 (15)       | 2 (1)  |
| <b>Respiratory, thoracic and mediastinal disorders</b> |                |        |               |        |
| Dyspnoea   | 58 (28)        | 18 (9) | 48 (24)       | 11 (6) |
| Cough  | 53 (26)        | 2 (1)  | 29 (15)       | 0 (0)  |
| Epistaxis  | 25 (12)        | 0 (0)  | 7 (4)         | 0 (0)  |
| <b>Skin and subcutaneous tissue disorders</b>          |                |        |               |        |
| Rash <sup>e</sup>                                      | 97 (47)        | 10 (5) | 14 (7)        | 0(0)   |
| Pruritus   | 40 (19)        | 1 (1)  | 16 (8)        | 0 (0)  |
| Nail Disorder  | 28 (14)        | 0 (0)  | 1 (1)         | 0 (0)  |
| Dry Skin   | 22 (11)        | 1 (1)  | 14 (7)        | 0 (0)  |
| Acne   | 21 (10)        | 0 (0)  | 2 (1)         | 0 (0)  |
| <b>Nervous system disorders</b>                        |                |        |               |        |
| Dysgeusia <sup>f</sup>                                 | 41 (20)        | 0 (0)  | 17 (9)        | 0 (0)  |
| Insomnia   | 24 (12)        | 1 (1)  | 30 (15)       | 0 (0)  |
| Depression   | 9 (4)          | 0 (0)  | 27 (14)       | 4 (2)  |

\* Common Toxicity Criteria for Adverse Events (CTCAE), Version 3.0.

a Includes oedema, facial oedema, and peripheral oedema

b Includes aphthous stomatitis, glossitis, mouth ulceration, mucositis, and stomatitis

c Includes infections not otherwise specified (NOS) and the following infections that occurred infrequently as distinct entities: abscess, bronchitis, cellulitis, herpes simplex, and herpes zoster

d Includes cystitis, dysuria, hematuria, urinary frequency, and urinary tract infection

e Includes eczema, exfoliative dermatitis, maculopapular rash, pruritic rash, pustular rash, rash (NOS), and vesiculobullous rash

f Includes taste loss and taste perversion.

The following selected adverse reactions were reported less frequently (<10%).

*Gastrointestinal Disorders* – Fatal bowel perforation (0.5%), abdominal distension (4.3%), dysphagia (3.4%), mouth pain (2.4%), gingivitis (2.4%), gastritis (1.0%), gastrointestinal haemorrhage (1.0%), haemorrhoidal haemorrhage (1.0%), lip haemorrhage (0.5%), mouth haemorrhage (0.5%), rectal haemorrhage (1.0%).

*Eye Disorders* - Conjunctivitis (including lacrimation disorder) (7.7%).

*Immune System* - Allergic/Hypersensitivity reactions (9%).

Angioneurotic oedema-type reactions have been observed in some patients who received TORISEL and ACE inhibitors concomitantly.

*Infections* – Rhinitis (9.6%), pneumonia (8%); upper respiratory tract infection occurred in 14 patients (7%), flu syndrome (3.4%), oral moniliasis (2.4%), sinusitis (1.9%), folliculitis (1.9%), wound infection/post-operative wound infection (1.0%), laryngitis (1.0%), fungal infection/fungal dermatitis (1.0%), sepsis (0.5%).

*General Disorders and Administration Site Conditions* - Diabetes mellitus (4.8%), dehydration (4.8%), impaired wound healing (1.4%), generalised oedema (0.5%).

*Respiratory, Thoracic and Mediastinal Disorders* – Pleural effusion (3.8%), interstitial lung disease (2.9%), including rare fatalities.

*Vascular* – Hypertension (7%); venous thromboembolism (including deep vein thrombosis and pulmonary embolus [including fatal outcomes]) (2%); thrombophlebitis (1%), pericardial effusion (1%).

*Nervous System Disorders* – Dizziness (9.1%), anxiety (7.7%), somnolence (6.7%), paresthesia (6.3%), convulsion (0.5%).

**TABLE 3: INCIDENCE OF SELECTED LABORATORY ABNORMALITIES IN PATIENTS WHO RECEIVED 25 MG IV TORISEL OR IFN- $\alpha$  IN THE RANDOMISED TRIAL**

| Laboratory Abnormality         | TORISEL<br>25 mg<br>n=208 |                      | IFN- $\alpha$<br>n=200 |                      |
|--------------------------------|---------------------------|----------------------|------------------------|----------------------|
|                                | All Grades*<br>n (%)      | Grades 3&4*<br>n (%) | All Grades*<br>n (%)   | Grades 3&4*<br>n (%) |
| <b>Any</b>                     | 208 (100)                 | 162 (78)             | 195 (98)               | 144 (72)             |
| <b>Haematology</b>             |                           |                      |                        |                      |
| Haemoglobin Decreased          | 195 (94)                  | 41 (20)              | 180 (90)               | 43 (22)              |
| Lymphocytes Decreased**        | 110 (53)                  | 33 (16)              | 106 (53)               | 48 (24)              |
| Neutrophils Decreased**        | 39 (19)                   | 10 (5)               | 58 (29)                | 19 (10)              |
| Platelets Decreased            | 84 (40)                   | 3 (1)                | 51 (26)                | 0 (0)                |
| Leukocytes Decreased           | 67 (32)                   | 1 (1)                | 93 (47)                | 11 (6)               |
| <b>Chemistry</b>               |                           |                      |                        |                      |
| Alkaline Phosphatase Increased | 141 (68)                  | 7 (3)                | 111 (56)               | 13 (7)               |
| AST Increased                  | 79 (38)                   | 5 (2)                | 103 (52)               | 14 (7)               |
| Calcium Decreased              | 82 (39)                   | 9 (4.3)              | 83 (42)                | 9 (5)                |
| Creatinine Increased           | 119 (57)                  | 7 (3)                | 97 (49)                | 2 (1)                |
| Glucose Increased              | 186 (89)                  | 33 (16)              | 128 (64)               | 6 (3)                |
| Phosphorus Decreased           | 102 (49)                  | 38 (18)              | 61 (31)                | 17 (9)               |
| Total Bilirubin Increased      | 16 (8)                    | 2 (1)                | 25 (13)                | 4 (2)                |

|                             |          |         |          |         |
|-----------------------------|----------|---------|----------|---------|
| Total Cholesterol Increased | 181 (87) | 5 (2)   | 95 (48)  | 2 (1)   |
| Triglycerides Increased     | 173 (83) | 92 (44) | 144 (72) | 69 (35) |
| Potassium Decreased         | 43 (21)  | 11 (5)  | 15 (8)   | 0 (0)   |

\*NCI CTC version 3.0

\*\*Grade 1 toxicity may be under-reported for lymphocytes and neutrophils.

### ***Mantle Cell Lymphoma***

Fifty-four patients were treated with TORISEL 175/75 in the initial treatment period in Study 3, a randomised, open-label trial comparing two TORISEL dosing regimens with an investigator's choice regimen (see Section 5.1 Pharmacodynamic properties - Clinical trials). During an additional 40 months of safety follow up, patients who had previously discontinued therapy or were receiving either investigator's choice regimen or TORISEL 175/25 were eligible to crossover to TORISEL 175/75 treatment. In this safety population TORISEL 175/75 n=57, TORISEL 175/25 n=56, and investigator's choice regimen n=54.

All treatment groups in the safety population experienced a high incidence of adverse events (over 95%). During the high dose part of TORISEL treatment (first three doses), approximately half the subjects had a dose reduction and two-thirds a dose delay. The dose delay was mostly 1-3 days. Table 4 lists the common events (incidence  $\geq 10\%$ ) that were considerably more frequent with TORISEL 175/75 than investigator choice therapy. Of the common events, only neutropenia (41% vs. 26%), leukopenia (41% vs. 18%), oedema (13% vs. 5%), dyspnoea (30% vs. 23%), constipation (19% vs 16%), lymphopenia (19% vs 12%) and sweating (13% vs. 2%) were considerably more frequent in the investigator choice Group than the TORISEL 175/75 Group.

**TABLE 4: INCIDENCE OF VERY COMMON ( $\geq 10\%$ ) ADVERSE EVENTS IN STUDY 3**

| <b>System Organ Class<br/>Adverse Event*</b> | <b>TORISEL 175/75<br/>N=57</b> | <b>Investigator Choice<br/>N=54</b> |
|--|--------------------------------|-------------------------------------|
| <b>Body as a Whole</b>                       |                                |                                     |
| Asthenia                                     | 39 (68)                        | 15 (28)                             |
| Fever  | 25 (44)                        | 18 (33)                             |
| Back pain                                    | 8 (14)                         | 2 (4)                               |
| Chest pain                                   | 6 (11)                         | 2 (4)                               |
| Headache                                     | 10 (18)                        | 5 (9)                               |
| Infection                                    | 19 (33)                        | 5 (9)                               |
| Pain   | 19 (33)                        | 2 (4)                               |
| <b>Gastrointestinal</b>                      |                                |                                     |
| Anorexia                                     | 23 (40)                        | 8 (15)                              |
| Diarrhoea                                    | 27 (47)                        | 6 (11)                              |
| Mucositis                                    | 21 (37)                        | 0 (0)                               |
| Nausea                                       | 14 (25)                        | 11 (20)                             |
| Rectal haemorrhage                           | 6 (11)                         | 1 (2)                               |
| Stomatitis                                   | 12 (21)                        | 3 (6)                               |
| Vomiting                                     | 8 (14)                         | 3 (6)                               |
| <b>Haematological</b>                        |                                |                                     |
| Thrombocytopenia                             | 45 (79)                        | 29 (54)                             |

| <b>System Organ Class<br/>Adverse Event*</b> | <b>TORISEL 175/75<br/>N=57</b> | <b>Investigator Choice<br/>N=54</b> |
|--|--------------------------------|-------------------------------------|
| Anaemia                                      | 31 (54)                        | 24 (44)                             |
| <b>Metabolic</b>                             |                                |                                     |
| Hypercholesteremia                           | 11 (19)                        | 0 (0)                               |
| Hyperglycemia                                | 9 (16)                         | 6 (11)                              |
| Hyperlipemia                                 | 7 (12)                         | 0 (0)                               |
| Hypocalcemia                                 | 6 (11)                         | 0 (0)                               |
| Hypokalaemia                                 | 14 (25)                        | 1 (2)                               |
| Hypophosphatemia                             | 7 (12)                         | 0 (0)                               |
| Lactic dehydrogenase<br>increased            | 6 (11)                         | 1 (2)                               |
| Peripheral oedema                            | 14 (25)                        | 9 (17)                              |
| Weight loss                                  | 10 (18)                        | 5 (9)                               |
| <b>Musculoskeletal</b>                       |                                |                                     |
| Arthralgia                                   | 12 (21)                        | 1 (2)                               |
| Muscle cramp                                 | 7 (12)                         | 1 (2)                               |
| <b>Neurological</b>                          |                                |                                     |
| Anxiety                                      | 9 (16)                         | 3 (6)                               |
| Dizziness                                    | 4 (7)                          | 1 (2)                               |
| Insomnia                                     | 12 (21)                        | 4 (7)                               |
| <b>Respiratory</b>                           |                                |                                     |
| Epistaxis                                    | 26 (47)                        | 3 (6)                               |
| Cough increased                              | 20 (35)                        | 6 (11)                              |
| Pneumonia                                    | 10 (18)                        | 6 (11)                              |
| Rhinitis                                     | 6 (11)                         | 3 (6)                               |
| Sinusitis                                    | 6 (11)                         | 0 (0)                               |
| Upper respiratory infection                  | 9 (165)                        | 2 (4)                               |
| <b>Skin</b>                                  |                                |                                     |
| Acne   | 6 (11)                         | 0 (0)                               |
| Dry skin                                     | 7 (12)                         | 1 (2)                               |
| Erythema                                     | 6 (11)                         | 2 (4)                               |
| Herpes Simplex                               | 6 (11)                         | 4 (7)                               |
| Nail disorder                                | 11 (19)                        | 1 (2)                               |
| Pruritus                                     | 16 (28)                        | 3 (6)                               |
| Rash   | 21 (37)                        | 6 (11)                              |
| <b>Special Senses</b>                        |                                |                                     |
| Taste perversion                             | 9 (16)                         | 1 (2)                               |
| <b>Urogenital</b>                            |                                |                                     |
| Unspecified                                  | 17 (30)                        | 6 (11)                              |

\* coded for COSTART dictionary

In the safety population there was a higher incidence of severe (Grade 3-4) adverse events, serious adverse events, and deaths within 14 days of last dose in the TORISEL groups than in

the investigator choice group. For severe adverse events, the incidences were 95%, 88% and 76% for TORISEL 175/75, TORISEL 175/25 and investigator choice respectively. For serious adverse events, the incidences were 60%, 61% and 28% and for deaths, 7%, 4% and 2%. Serious reactions with TORISEL were fever, diarrhoea, infection, general physical health deterioration, thrombocytopenia, neutropenia, infection, interstitial lung disease (pneumonitis), bowel perforation, hypersensitivity and hyperglycaemia/glucose intolerance.

Deaths due to adverse events occurred in two (4%) temsirolimus 175/75 patients and three (6%) temsirolimus 175/25 patients. There were no deaths due to adverse events in patients receiving investigator choice. Three deaths in the TORISEL groups were considered possibly related to the drug, one each due to duodenal perforation, sepsis and pneumonitis. The treatment and observation periods for temsirolimus were considerably longer than for investigator choice (median 12-14 weeks vs. 5 weeks for treatment), which would account for some of the difference in adverse event profiles.

The incidence of thrombocytopenia with TORISEL 175/75 was 79% compared with 54% with investigator choice. Both the drug and the underlying disease are likely to be contributing factors. The majority of cases of thrombocytopenia were severe. Minor bleeding, in particular epistaxis, was common and more frequent in this trial than in renal carcinoma patients.

Adverse events of higher incidence with TORISEL in this trial compared with previous experience in the lower dose renal carcinoma trial were thrombocytopenia, neutropenia, infection, diarrhoea, asthenia and pneumonitis.

Elderly patients ( $\geq 65$  years) may be more likely to experience certain adverse reactions with TORISEL including anxiety, depression, dyspnoea, leukopenia, myalgia, taste loss and upper respiratory infection.

Table 5 contains the incidence of ADRs occurring at all frequencies and the incidence of Grade 3 & 4 ADRs for the TORISEL 175/75 mg treatment group in Study 3. The information in the table is based on the MedDRA dictionary. The frequency categories are Very common:  $\geq 1/10$  and Common:  $\geq 1/100$  to  $<1/10$

**Table 5: Adverse Reactions Reported in Patients who Received Torisel 175/75 mg in Study 3 n=57**

| System Organ Class          | Frequency   | Adverse Reactions*  | All Grades n (%) | Grade 3 & 4 n (%) |
|-----------------------------|-------------|---|------------------|-------------------|
| Infections and infestations | Very common | Bacterial and viral infections (including infection, viral infection, influenza, bacterial infection, cellulitis, bronchitis, sinusitis, herpes zoster, herpes simplex, herpes virus infection, oral herpes) <sup>a</sup> | 25 (43.9)        | 10 (17.5)         |
|                             |             | Pneumonia   | 10 (17.5)        | 6 (10.5)          |
|                             |             | Upper respiratory tract infection   | 9 (15.8)         | 0 (0)             |
|                             | Common      | Pharyngitis   | 1 (1.8)          | 0 (0)             |

**Table 5: Adverse Reactions Reported in Patients who Received Torisel 175/75 mg in Study 3 n=57**

| System Organ Class                   | Frequency   | Adverse Reactions*   | All Grades n (%) | Grade 3 & 4 n (%) |
|--------------------------------------|-------------|--|------------------|-------------------|
|                                      |             | Sepsis (including septic shock) <sup>a</sup>                                 | 3 (5.3)          | 3 (5.3)           |
|                                      |             | Sinusitis  | 5 (8.8)          | 0 (0)             |
|                                      |             | Candidiasis (including oral and anal candidiasis) and fungal skin infections | 5 (8.8)          | 0 (0)             |
|                                      |             | Urinary tract infection  | 3 (5.3)          | 0 (0)             |
|                                      |             | Rhinitis   | 5 (9.3)          | 0 (0)             |
|                                      |             | Folliculitis   | 1 (1.8)          | 0 (0)             |
| Blood and lymphatic system disorders | Very common | Thrombocytopenia <sup>b</sup>  | 33 (57.9)        | 26 (45.6)         |
|                                      |             | Anaemia  | 25 (43.9)        | 8 (14.0)          |
|                                      |             | Neutropenia <sup>b</sup>   | 15 (26.3)        | 10 (17.5)         |
|                                      |             | Leucopenia   | 8 (14.0)         | 4 (7.0)           |
|                                      |             | Lymphopenia  | 6 (11.1)         | 4 (7.0)           |
| Immune system disorders              | Common      | Hypersensitivity reactions/drug hypersensitivity                             | 3 (5.3)          | 0 (0)             |
| Metabolism and nutrition disorders   | Very common | Hypokalaemia   | 14 (24.6)        | 4 (7.0)           |
|                                      |             | Anorexia   | 23 (40.4)        | 2 (3.5)           |
|                                      |             | Hyperglycaemia <sup>c</sup>  | 9 (15.8)         | 6 (10.5)          |
|                                      |             | Hypercholesterolaemia  | 10 (17.5)        | 0 (0)             |
|                                      |             | Hypocalcaemia  | 6 (10.5)         | 1 (1.8)           |
|                                      | Common      | Dehydration  | 3 (5.3)          | 2 (3.5)           |
|                                      |             | Hypophosphataemia  | 5 (8.8)          | 1 (1.8)           |
|                                      |             | Hyperlipaemia  | 5 (9.3)          | 1 (1.9)           |
|                                      |             | Hyperlipidaemia  | 1 (1.8)          | 0 (0)             |
|                                      |             | Hypotriglyceridaemia   | 5 (8.8)          | 0 (0)             |
| Diabetes mellitus                    | 2 (3.5)     | 1 (1.8)  |                  |                   |
| Psychiatric disorders                | Very common | Insomnia   | 13 (22.8)        | 0 (0)             |
|                                      |             | Anxiety  | 9 (15.8)         | 0 (0)             |
|                                      | Common      | Depression   | 3 (5.3)          | 0 (0)             |
| Nervous system disorders             | Very common | Dysgeusia  | 11 (19.3)        | 0 (0)             |
|                                      |             | Headache   | 10 (17.5)        | 1 (1.8)           |
|                                      | Common      | Paresthesia  | 4 (7.0)          | 0 (0)             |
|                                      |             | Dizziness  | 4 (7.0)          | 0 (0)             |
|                                      |             | Ageusia  | 3 (5.3)          | 0 (0)             |
| Eye disorders                        | Common      | Conjunctivitis   | 4 (7.0)          | 0 (0)             |
|                                      |             | Eye haemorrhage  | 2 (3.5)          | 0 (0)             |
| Vascular disorders                   | Common      | Venous thromboembolism (including deep vein thrombosis)                      | 1 (1.8)          | 0 (0)             |
|                                      |             | Hypertension   | 2 (3.5)          | 0 (0)             |
|                                      |             | Dyspnoea   | 13 (22.8)        | 5 (8.8)           |

**Table 5: Adverse Reactions Reported in Patients who Received Torisel 175/75 mg in Study 3 n=57**

| System Organ Class                                    | Frequency   | Adverse Reactions*   | All Grades n (%) | Grade 3 & 4 n (%) |
|---|-------------|--|------------------|-------------------|
| Respiratory, thoracic and mediastinal disorders       | Very common | Epistaxis  | 26 (45.6)        | 1 (1.8)           |
|   |             | Cough  | 20 (35.1)        | 1 (1.8)           |
|   |             | Pleural effusion   | 6 (10.5)         | 2 (3.5)           |
|   | Common      | Interstitial lung disease <sup>d</sup>   | 6 (10.5)         | 3 (5.3)           |
| Gastrointestinal disorders                            | Very common | Abdominal pain   | 11 (19.3)        | 1 (1.8)           |
|   |             | Vomiting   | 8 (14.0)         | 0 (0)             |
|   |             | Stomatitis   | 14 (24.6)        | 1 (1.8)           |
|   |             | Diarrhoea  | 27 (47.4)        | 5 (8.8)           |
|   |             | Nausea   | 14 (24.6)        | 0 (0)             |
|   |             | Constipation   | 9 (15.8)         | 0 (0)             |
|   |             | Gastrointestinal haemorrhage (including rectal, anal and mouth haemorrhage) <sup>a</sup>     | 8 (14.0)         | 2 (3.6)           |
|   |             | Dysphagia  | 6 (10.5)         | 0 (0)             |
|   | Common      | Duodenal perforation   | 1 (1.8)          | 1 (1.8)           |
|   |             | Gingivitis   | 2 (3.5)          | 0 (0)             |
|   |             | Gastritis  | 3 (5.3)          | 1 (1.8)           |
|   |             | Oral pain  | 3 (5.3)          | 1 (1.8)           |
|   |             | Aphthous stomatitis  | 3 (5.3)          | 0 (0)             |
|   |             | Abdominal distension   | 1 (1.8)          | 0 (0)             |
| Skin and subcutaneous tissue disorders                | Very common | Rash (including rash, pruritic rash, maculopapular rash, pustular rash, eczema) <sup>a</sup> | 26 (45.6)        | 3 (5.3)           |
|   |             | Pruritus (including pruritis generalised)  | 16 (28.1)        | 3 (5.3)           |
|   |             | Dry skin   | 7 (12.3)         | 0 (0)             |
|   | Common      | Acne   | 2 (3.5)          | 0 (0)             |
|   |             | Moniliasis (including moniliasis, oral moniliasis) <sup>a</sup>                              | 2 (3.7)          | 0 (0)             |
|   |             | Dermatitis   | 2 (3.5)          | 0 (0)             |
|   |             | Nail disorder  | 5 (8.8)          | 0 (0)             |
|   |             | Eccymosis  | 3 (5.3)          | 0 (0)             |
|   |             | Petechiae  | 3 (5.3)          | 0 (0)             |
|   |             |  |                  |                   |
| Musculoskeletal, connective tissue and bone disorders | Very common | Back pain  | 8 (14.0)         | 0 (0)             |
|   |             | Arthralgia   | 11 (19.3)        | 1 (1.9)           |
|   | Common      | Myalgia  | 3 (5.3)          | 0 (0)             |
| Renal and urinary disorders                           | Common      | Renal failure  | 1 (1.8)          | 0 (0)             |
| General disorders and                                 | Very common | Oedema (including peripheral oedema, scrotal oedema, genital oedema) <sup>a</sup>            | 17 (29.8)        | 1 (1.8)           |

**Table 5: Adverse Reactions Reported in Patients who Received Torisel 175/75 mg in Study 3 n=57**

| System Organ Class             | Frequency | Adverse Reactions*                   | All Grades n (%) | Grade 3 & 4 n (%) |
|--------------------------------|-----------|--------------------------------------|------------------|-------------------|
| administration site conditions |           | Fatigue                              | 26 (45.6)        | 4 (7.0)           |
|                                |           | Asthenia                             | 12 (21.1)        | 5 (8.8)           |
|                                |           | Pain                                 | 7 (12.3)         | 1 (1.8)           |
|                                |           | Pyrexia                              | 23 (40.4)        | 3 (5.3)           |
|                                |           | Mucosal inflammation                 | 20 (35.1)        | 2 (3.5)           |
|                                |           | Chills                               | 15 (26.3)        | 1 (1.8)           |
|                                | Common    | Chest pain                           | 5 (8.8)          | 0 (0)             |
| Investigation                  | Common    | Blood creatinine increased           | 5 (8.8)          | 0 (0)             |
|                                |           | Increased aspartate aminotransferase | 2 (3.5)          | 1 (1.8)           |
|                                |           | Increased alanine aminotransferase   | 1 (1.8)          | 1 (1.8)           |

\* coded for MedDRA dictionary

<sup>a</sup>Body system totals are not necessarily the sum of the individual adverse events since a subject may report two or more different adverse events in the same body system.

<sup>b</sup>Grades 3 and 4 (thrombocytopenia) are defined as  $2550 \text{ platelets} \times 109/\text{L}$  and  $<25 \text{ platelets} \times 109/\text{L}$ , respectively. Grades 3 and 4 (neutropenia) are defined as  $0.5 - 1.0 \text{ neutrophils} \times 109/\text{L}$  and  $<0.5 \text{ neutrophils} \times 109/\text{L}$ , respectively.

<sup>c</sup>Patients should be advised that treatment with TORISEL may be associated with an increase in blood glucose levels in patients with or without diabetes.

<sup>d</sup>Interstitial lung disease is defined by a cluster of related Preferred Terms: interstitial lung disease (n=1), pneumonitis (n=3), alveolitis allergic (n=1), pulmonary fibrosis (n=1). One case of fatal pneumonitis was reported in a mantle cell lymphoma patient receiving 175/25 mg/week that is not included in this table.

Serious adverse reactions observed in clinical trials of TORISEL for renal cell carcinoma but not in clinical trials of TORISEL for mantle cell lymphoma include: anaphylaxis, impaired wound healing, renal failure with fatal outcomes, pericardial effusion (including haemodynamically significant pericardial effusions requiring intervention), convulsions, and pulmonary embolus.

### Post-marketing experience

Additional adverse events reported from worldwide marketing experience with TORISEL, occurring under circumstances where causal relationship with TORISEL is uncertain. The events are listed using the CIOMS frequency categories as follows:

Very common  $\geq 10\%$   
 Common  $\geq 1\%$   
 Uncommon:  $\geq 0.1\%$  and  $<1\%$   
 Rare:  $\geq 0.01\%$  and  $<0.1\%$   
 Very rare:  $< 0.01\%$

### Cardiac disorders

Uncommon: Pericardial effusion (including haemodynamically significant pericardial effusions requiring intervention).

## **Respiratory, thoracic and mediastinal disorders**

Common: Pleural effusion.

## **Nervous system disorders**

Uncommon: Convulsion.

## **Musculoskeletal and connective tissue disorders**

Common: Myalgia (including myalgia, leg cramps).

## **Infections and Infestations**

Rare: Pneumocystis jiroveci pneumonia, some with fatal outcomes (see Section 4.4 Special warnings and precautions for use).

The following adverse reactions have been observed in patients receiving temsirolimus: rhabdomyolysis, Stevens-Johnson syndrome, pancreatitis, cholecystitis, and cholelithiasis.

Angioneurotic oedema-type reactions have been reported in patients who received temsirolimus, including in some patients who received temsirolimus and ACE-inhibitors concomitantly.

## **Reporting suspected adverse effects**

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefit-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at [www.tga.gov.au/reporting-problems](http://www.tga.gov.au/reporting-problems).

## **4.9 Overdose**

There is no specific treatment for temsirolimus overdose; however, temsirolimus has been safely administered to patients with cancer with repeated intravenous doses as high as 220 mg/m<sup>2</sup>.

For information on the management of overdose, contact the Poisons Information Centre on 11 26 (Australia).

# **5. PHARMACOLOGICAL PROPERTIES**

## **5.1 Pharmacodynamic properties**

### **Mechanism of action**

Temsirolimus is a selective inhibitor of mTOR (mammalian target of rapamycin). In humans, sirolimus is a major metabolite of temsirolimus that was equipotent to temsirolimus at inhibiting mTOR phosphorylation, and at inhibiting cell proliferation or tumour cell growth both in tissue culture and in nude mouse xenograft models. Temsirolimus binds to an intracellular protein (FKBP-12), and the protein-drug complex binds and inhibits the activity

of mTOR that controls cell proliferation. Inhibition of mTOR activity results in a G1 growth arrest in treated tumour cells resulting from selective disruption of translation of cell cycle regulatory proteins, such as D-type cyclins, c-myc, and ornithine decarboxylase. Temsirolimus exerts its effect by binding in a complex with FKBP-12 and mTOR. When mTOR is bound in this complex, its ability to phosphorylate, and thereby control the activity of protein translation factors (4E-BP1 and S6K, both downstream of mTOR in the PI3 kinase/AKT pathway) that control cell division, is blocked.

In addition to regulating cell cycle proteins, mTOR can regulate translation of the hypoxia-inducible factors, HIF-1 and HIF-2 alpha. These transcription factors regulate the ability of tumours to adapt to hypoxic microenvironments and to produce the angiogenic factor vascular endothelial growth factor (VEGF). The anti-tumour effect of temsirolimus, therefore, may also in part, stem from its ability to depress levels of HIF and VEGF in the tumour or tumour microenvironment, thereby impairing vessel development.

### ***Concentration-Effect Relationship***

The effect of temsirolimus intravenous treatment on the inhibition of phosphorylation of S6-ribosomal protein in circulating lymphocytes was examined in 30 healthy subjects. Data indicate that inhibition of protein phosphorylation was rapid and dose-dependent. Following a single 25 mg intravenous dose of temsirolimus, 20% and 50% of inhibition of S6-ribosomal protein was shown for at least 8 days and 3 days, respectively.

### **Clinical trials**

#### ***Renal Cell Carcinoma***

The safety and efficacy of TORISEL in the treatment of advanced renal cell carcinoma (RCC) were studied in the following two randomised clinical trials.

#### ***Study 1***

Study 1 was a Phase 3, multi-centre, 3-arm, randomised, open-label study in previously untreated patients with advanced renal cell carcinoma (RCC) and with 3 or more of 6 pre-selected risk factors indicating a poor prognosis (less than 1 year from time of initial RCC diagnosis to randomisation, Karnofsky performance status of 60 or 70, haemoglobin less than the lower limit of normal, corrected calcium of greater than 10 mg/dL, lactate dehydrogenase > 1.5 times the upper limit of normal, more than 1 metastatic organ site). The primary study endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), clinical benefit rate, time to treatment failure (TTF), and quality adjusted survival measurement. Patients were stratified for prior nephrectomy status within 3 geographic regions and were randomly assigned (1:1:1) to receive interferon alpha (IFN- $\alpha$ ) alone (n=207), TORISEL alone (25 mg weekly; n=209), or the combination of IFN- $\alpha$  and TORISEL (n=210).

The combination arm did not exhibit a positive clinical benefit-risk ratio compared to IFN- $\alpha$ . Treatment with the combination of TORISEL 15 mg and IFN- $\alpha$  resulted in a statistically significant increase in the incidence of certain grade 3-4 adverse events (weight loss, hyperlipidaemia, anaemia, neutropenia, thrombocytopenia and mucosal inflammation) when compared to the adverse events observed in the IFN- $\alpha$  or TORISEL 25 mg alone arms. The combination of TORISEL 15 mg and IFN- $\alpha$  did not result in a significant increase in OS when compared to IFN- $\alpha$  alone (median 8.4 vs. 7.3 months, hazard ratio = 0.96, p = 0.6965).

Information on the TORISEL 25 mg alone and IFN- $\alpha$  alone arms is described in this section. The demographic and disease characteristics of the study population are shown in Table 6. Baseline demographic and disease characteristics were well balanced across treatment arms.

**TABLE 6: DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS FOR PATIENTS IN CLINICAL STUDY 1**


| <b>Characteristic</b>           | <b>TORISEL<br/>n (%)</b> | <b>IFN-<math>\alpha</math><br/>n (%)</b> |
|---------------------------------|--------------------------|--|
| Total patients in treatment arm | 209                      | 207                                      |
| Age                             |                          |  |
| < 65 years                      | 145 (69.4)               | 142 (68.6)                               |
| > 65 years                      | 64 (30.6)                | 65 (31.4)                                |
| Sex                             |                          |  |
| Female                          | 70 (33.5)                | 59 (28.5)                                |
| Male                            | 139 (66.5)               | 148 (71.5)                               |
| Race                            |                          |  |
| White                           | 186 (89.0)               | 191 (92.3)                               |
| Asian                           | 6 (2.9)                  | 4 (1.9)                                  |
| Black                           | 9 (4.3)                  | 8 (3.9)                                  |
| Other                           | 8 (3.8)                  | 4 (1.9)                                  |
| Prior nephrectomy               |                          |  |
| No                              | 70 (33.5)                | 68 (32.9)                                |
| Yes                             | 139 (66.5)               | 139 (67.1)                               |
| Stage of disease at baseline    |                          |  |
| Stage IV                        | 200 (95.7)               | 201 (97.1)                               |
| Recurrent Stage II              | 1 (0.5)                  | 1 (0.5)                                  |
| Recurrent Stage III             | 8 (3.8)                  | 5 (2.4)                                  |
| Primary cell type               |                          |  |
| Clear                           | 169 (82.0)               | 170 (82.5)                               |
| Indeterminate                   | 24 (11.7)                | 23 (11.2)                                |
| Non-clear                       | 13 (6.3)                 | 13 (6.3)                                 |
| Unknown                         | 3                        | 1  |

In Study 1, TORISEL was associated with a statistically significant advantage over IFN- $\alpha$  in the primary endpoint of OS (time from randomisation to death). The TORISEL arm showed a 49% increase in median OS compared with the IFN- $\alpha$  arm.

Figure 1 is a Kaplan-Meier plot of OS in Study 1. TORISEL was also associated with statistically significant advantages over IFN- $\alpha$  in the secondary endpoints of PFS (time from randomisation to disease progression or death, censored at the last tumour evaluation date); TTF (time from randomisation to disease progression, death, withdrawal from treatment due to an adverse event, withdrawal of voluntary consent, or loss to follow up) and clinical benefit rate (complete response, partial response, or stable disease for > 24 weeks). The evaluations of PFS, ORR, and clinical benefit rate were based on blinded independent radiologic assessment of tumour response using Response Evaluation Criteria in Solid Tumors (RECIST)-

based criteria. TTF utilised the investigator’s assessment of progression. Efficacy results are summarised in Table 7.

**FIGURE 1: KAPLAN-MEIER CURVES FOR OVERALL SURVIVAL - STUDY 1**



**TABLE 7: SUMMARY OF EFFICACY RESULTS IN TORISEL CLINICAL STUDY 1**

| Parameter   | TORISEL<br>N=209  | IFN- $\alpha$<br>N=207 | P-value <sup>a</sup> | Hazard ratio<br>(95% CI) <sup>b</sup> |
|---|-------------------|------------------------|----------------------|---------------------------------------|
| Median Overall Survival<br>Months (95% CI)              | 10.9 (8.6, 12.7)  | 7.3 (6.1, 8.8)         | 0.0078*              | 0.73 (0.58, 0.92)                     |
| Median Progression-<br>Free Survival<br>Months (95% CI) | 5.5 (3.9, 7.0)    | 3.1 (2.2, 3.8)         | 0.0001               | 0.66 (0.53, 0.81)                     |
| Overall Response Rate<br>% (95% CI)                     | 8.6 (4.8, 12.4)   | 4.8 (1.9, 7.8)         | 0.1232 <sup>c</sup>  | NA                                    |
| Median Time to<br>Treatment Failure<br>Months (95% CI)  | 3.8 (3.5, 3.9)    | 1.9 (1.7, 1.9)         | <0.0001              | 0.61 (0.50, 0.74)                     |
| Clinical Benefit Rate<br>% (95% CI)                     | 32.1 (25.7, 38.4) | 15.5 (10.5, 20.4)      | <0.0001 <sup>c</sup> | NA                                    |

CI = confidence interval; NA = not applicable.

\* A comparison is considered statistically significant if the p-value is < 0.0159 (O’Brien-Fleming boundary at 446 deaths).

a. Based on log-rank test stratified by prior nephrectomy and region.

b. Based on Cox proportional hazard model stratified by prior nephrectomy and region.

c. Based on Cochran-Mantel-Haenszel test stratified by prior nephrectomy and region.

In clinical Study 1, 31% of patients treated with TORISEL were 65 years or older. In patients younger than 65, median OS for patients treated with TORISEL was 12 months (95% CI 9.9-14.5) with hazard ratio of 0.62 (95% CI 0.47-0.82), compared with IFN- $\alpha$ . In patients 65 years or older, median OS was 8.6 months (95% CI 6.4-11.5) with hazard ratio of 1.08 (95% CI 0.71-1.63) compared to those treated with IFN- $\alpha$ .

### *Quality Adjusted Survival*

Quality adjusted survival was compared across treatment groups using the quality-adjusted time without symptoms and toxicities (Q-TWiST) approach. Survival was value-weighted by the patient based on presence or absence of toxicity or progression by completing the EuroQoL 5D (EQ-5D) scale at baseline, Weeks 12 and 32, when a Grade 3 or 4 toxicity was reported, upon relapse or progression, or upon withdrawal from the study. TORISEL is associated with a statistically significant increase in quality adjusted survival (Q-TWiST) time of an estimated 1.3 months (7.0 vs. 5.7 months, 23%) as compared to IFN- $\alpha$ .

### **Study 2**

Study 2 was a randomised, double-blind, multi-centre, outpatient trial to evaluate the efficacy, safety, and pharmacokinetics of three dose levels of TORISEL when administered to previously treated patients with advanced RCC. The primary efficacy endpoint was ORR. Clinical benefit rate, PFS, and OS were also evaluated. PFS was defined as time from the first dose of TORISEL to disease progression or death. One hundred eleven (111) patients were randomly assigned in a 1:1:1 ratio to receive 25 mg, 75 mg, or 250 mg TORISEL IV weekly. In the 25 mg arm, all patients had metastatic disease; 4 (11%) had no prior chemo- or immunotherapy; 17 (47%) had one prior treatment; and 15 (42%) had 2 or more prior treatments for RCC. Twenty-seven (27, 75%) had undergone a nephrectomy. Twenty-four (24, 67%) were Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 1, and 12 (33%) were ECOG PS = 0.

For patients treated weekly with 25 mg IV TORISEL, the median OS was 13.8 months (95% CI: 9.0, 18.7 months); median PFS was 6.3 months (95% CI: 3.6, 7.8 months); ORR was 5.6% (95% CI: 0.7, 18.7%), and clinical benefit rate was 52.8% (95% CI: 35.5, 69.6%).

### ***Mantle Cell Lymphoma***

The safety and efficacy of IV temsirolimus for the treatment of relapsed and/or refractory mantle cell lymphoma was studied in the following Phase 3 clinical study.

### **Study 3**

Study 3 is a controlled, randomised, open-label, multicenter, outpatient study comparing 2 different dosing regimens of TORISEL with an investigator's choice of therapy in patients with relapsed and/or refractory mantle cell lymphoma. Subjects with mantle cell lymphoma that was confirmed by histology, immunophenotype, and cyclin D1 analysis who had received 2 to 7 prior therapies that included anthracyclines and alkylating agents, and rituximab (and could include haematopoietic stem cell transplant) and whose disease was relapsed and/or refractory were eligible for the study. Subjects were randomly assigned in a 1:1:1 ratio to receive TORISEL 175/75 - temsirolimus IV 175 mg (3 successive weekly doses) followed by 75 mg weekly (n=54), TORISEL 175/25 - temsirolimus IV 175 mg (3 successive weekly doses) followed by 25 mg weekly (n=54), or the investigator's choice of single-agent treatment (as specified in the protocol; n=54).

The primary endpoint of the study was PFS. Secondary endpoints included OS and ORR. ORR was assessed using the International Workshop Modified Response Criteria for Non-Hodgkin's Lymphoma. PFS and ORR were assessed by blinded independent radiologists and oncologists.

Investigator's choice therapies included: gemcitabine (IV: 22 [41.5%]), fludarabine (IV: 12 [22.6%] or oral: 2 [3.8%]), chlorambucil (oral: 3 [5.7%]), cladribine (IV: 3 [5.7%]), etoposide (IV: 3 [5.7%]), cyclophosphamide (oral: 2 [3.8%]), thalidomide (oral: 2 [3.8%]), vinblastine (IV: 2 [3.8%]), alemtuzumab (IV: 1 [1.9%]), and lenalidomide (oral: 1 [1.9%]).

The median treatment time was 12 weeks for TORISEL 175/75, 14 weeks for TORISEL 175/25 and 5 weeks for investigator's choice. TORISEL 175/75 significantly increased tumour response and progression-free survival compared with investigator choice (see Table 8). TORISEL 175/25 did not differ significantly from investigator choice. The study was not powered to assess differences in OS.

**TABLE 8: SUMMARY OF EFFICACY RESULTS IN TEMSIROLIMUS CONCENTRATE FOR INJECTION CLINICAL STUDY 3**

|   | <b>TORISEL<br/>175/75<br/>N=54</b> | <b>TORISEL<br/>175/25<br/>N=54</b> | <b>Investigator<br/>Choice<br/>N=54</b> |
|---|------------------------------------|------------------------------------|---|
| Objective Response Rate<br>[95% CI]                             | 22.2%<br>[11.1%, 33.3%]            | 5.6%<br>[0.0%, 11.7%]              | 1.9%                                    |
| Difference from Investigator Choice<br>[95% CI]                 | 20.3%<br>[8.75%, 32%]              | 3.7%<br>[-3.4%, 10.8%]             |   |
| Fisher's Exact p value  | 0.0019                             | 0.6179                             |   |
| Progression-Free Survival median<br>months                      | 4.8                                | 3.4                                | 1.9                                     |
| Hazard Ratio vs. Investigator Choice<br>[97.5% CI] <sup>a</sup> | 0.44<br>[0.25, 0.78]               | 0.65<br>[0.39, 1.10]               |   |
| Log-Rank p value  | 0.0009                             | 0.0618                             |   |
| Overall Survival median months                                  | 11.1                               | 8.8                                | 9.5                                     |
| Hazard Ratio vs. Investigator Choice<br>[95% CI] <sup>a</sup>   | 0.77<br>[0.46, 1.28]               | 0.98<br>[0.60, 1.62]               |   |
| Log-Rank p value  | 0.3053                             | 0.9515                             |   |

Abbreviations: CI = confidence interval.

<sup>a</sup> Compared with Investigator's Choice based on Cox proportional hazard model. In Study 3, there was no difference in efficacy in patients with respect to age, sex, race, geographic region, or baseline disease characteristics.

## 5.2 Pharmacokinetic properties

### Absorption

Following administration of a single 25 mg intravenous dose of temsirolimus in patients with cancer, mean  $C_{max}$  in whole blood was 585 ng/mL (coefficient of variation, CV=14%), and mean AUC in blood was 1627 ng.h/mL (CV=26%).

### Distribution

Temsirolimus exhibits a polyexponential decline in whole blood concentrations and distribution and is attributable by preferential binding to FKBP-12 in blood cells. The mean (standard deviation, SD) dissociation constant ( $K_d$ ) of binding was 5.1 (3.0) ng/mL, denoting the concentration at which 50% of binding sites in blood cells were occupied. Temsirolimus distribution is dose-dependent with mean (10th, 90th percentiles) maximal specific binding in blood cells of 1.4 mg (0.47 to 2.5 mg). Following a single 25 mg intravenous dose, mean steady-state volume of distribution in whole blood of patients with cancer was 172 litres. Plasma protein binding is approximately 89%.

### Metabolism

Sirolimus, an equally potent metabolite to temsirolimus was observed as the principal metabolite in humans following intravenous treatment. During in-vitro temsirolimus metabolism studies, sirolimus, seco-temsirolimus and seco-sirolimus, were observed; additional metabolic pathways were hydroxylation, reduction and demethylation. Sirolimus and temsirolimus are metabolised predominantly by CYP3A4. Following a single 25 mg intravenous dose in patients with cancer, sirolimus AUC was 2.7-fold that of temsirolimus AUC, due principally to the longer half-life of sirolimus.

### Excretion

Following a single 25 mg intravenous dose of temsirolimus in patients with cancer, temsirolimus mean (CV) systemic clearance was 16.2 (22%) L/h. Mean half-lives of temsirolimus and sirolimus were 17.3 hr and 54.6 hr, respectively. Following administration of [ $^{14}$ C]-labelled temsirolimus, excretion was predominantly via the faeces (78%), with renal elimination of drug and metabolites accounting for 4.6% of the administered dose.

### Special Populations

#### *Elderly*

In population pharmacokinetic-based data analyses, age did not have a significant effect on the disposition of temsirolimus or sirolimus metabolite.

#### *Paediatric*

There are no data available for paediatric patients.

#### *Gender*

In population pharmacokinetic-based data analyses, gender did not have a significant effect on the disposition of temsirolimus or sirolimus metabolite.

### ***Patients with renal impairment***

Temsirolimus elimination through kidneys is low. Since differences in creatinine clearance do not affect temsirolimus disposition, no change in temsirolimus intravenous treatment regimen is required for patients with renal impairment (see Section 4.2 Dose and method of administration).

### ***Patients with hepatic insufficiency or hepatic impairment***

Temsirolimus is cleared predominantly by the liver. No data are currently available regarding the influence of hepatic dysfunction and/or hepatic metastases on temsirolimus disposition.

Temsirolimus is contraindicated in patients with bilirubin >1.5 x ULN (see Section 4.3 Contraindications and Section 4.4 Special warnings and precautions for use).

### ***Effects of food***

The effect of food on exposure following an intravenous dose of temsirolimus was not examined.

## **5.3 Preclinical safety data**

### **Genotoxicity**

Temsirolimus was not genotoxic in a battery of in vitro (bacterial reverse mutation in *Salmonella typhimurium* and *Escherichia coli*, forward mutation in mouse lymphoma cells, and chromosome aberrations in Chinese hamster ovary cells) and in vivo (mouse micronucleus) assays.

### **Carcinogenicity**

Carcinogenicity studies have not been conducted with temsirolimus. However, sirolimus, the major metabolite of temsirolimus in humans, was carcinogenic in mice and rats. Increased incidences of lymphoma, hepatocellular adenoma and carcinoma in mice, and testicular adenoma in rats were reported following oral dosing of sirolimus in carcinogenicity studies.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

#### **Temsirolimus concentrate for injection vial:**

ethanol absolute,

dl-alpha-tocopherol

propylene glycol

citric acid.

#### **Diluent vial:**

polysorbate 80

macrogol 400

ethanol absolute.

## 6.2 Incompatibilities

TORISEL Concentrate for Injection should not be added directly to aqueous infusion solutions. Direct addition of TORISEL Concentrate for Injection to aqueous solutions will result in precipitation of drug. Always combine TORISEL Concentrate for Injection with diluent for TORISEL Concentrate for Injection before adding to infusion solutions. It is recommended that TORISEL be administered in 0.9% sodium chloride injection after combining with diluent. The stability of temsirolimus in other infusion solutions has not been evaluated. Addition of other drugs or nutritional agents to admixtures of temsirolimus in sodium chloride injection has not been evaluated and should be avoided. Temsirolimus is degraded by both acids and bases, and thus combinations of temsirolimus with agents capable of modifying solution pH should be avoided.

## 6.3 Shelf life

In Australia, information on the shelf life can be found on the public summary of the Australian Register of Therapeutic Goods (ARTG). The expiry date can be found on the packaging.

## 6.4 Special precautions for storage

### Components

TORISEL Concentrate for Injection and diluent should be protected from excessive room light and sunlight during handling and preparation of admixtures. TORISEL Concentrate for Injection should be inspected visually for particulate matter and discoloration following reconstitution and prior to administration. Bags/containers that come in contact with TORISEL Concentrate for Injection must be made of glass, polyolefin, or polyethylene.

TORISEL Concentrate for Injection must be refrigerated (2°C to 8°C) and protected from light. TORISEL Concentrate for Injection is stable for 36 months under these storage conditions.

Diluent for TORISEL Concentrate for Injection is stable for 36 months when stored below 25°C. The diluent may be stored at controlled room temperature until packaged with product, at which time it is refrigerated and protected from light.

The drug concentrate-diluent mixture is stable for up to 24 hours at controlled room temperature 20°C to 25°C.

### Admixtures

Once the concentrate is combined with the provided diluent, inject the mixture rapidly into 0.9% sodium chloride injection. To reduce microbiological hazard, use as soon as practical after preparation. Administration of the final diluted infusion solution should be completed within six hours from the time that the drug solution /diluent mixture is added to the sodium chloride injection. If storage is necessary, store at room temperature and protect from excessive light and sunlight.

TORISEL is for single use in one patient only. Discard any residue.

## 6.5 Nature and contents of container

Each carton of TORISEL contains two vials. One vial, which has a lime coloured flip-top seal, contains the temsirolimus concentrate and the other, which has a white coloured flip-top seal, contains the diluent. Both vials contain a small overfill to allow administration of 25 mg of temsirolimus.

## 6.6 Special precautions for disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

## 6.7 Physicochemical properties

Temsirolimus is a white to off-white powder. It is non-hygroscopic. Temsirolimus is insoluble in water and soluble in ethanol. It has no ionisable functional groups and its solubility is independent of pH.

Temsirolimus is the 2,2-bis(hydroxymethyl) propionic acid ester of sirolimus, a macrocyclic lactone produced by *Streptomyces hygroscopicus*.


The chemical name is:

(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentacontine-1,5,11,28,29(4H,6H,31H)-pentone 4'-[2,2-bis(hydroxymethyl)propionate];

or Rapamycin, 42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate].

### Chemical structure

The structural formula of temsirolimus is shown below:



Molecular Formula: C<sub>56</sub>H<sub>87</sub>NO<sub>16</sub>

Molecular Weight: 1030.3

**CAS number**

162635-04-3

**7. MEDICINE SCHEDULE (POISONS STANDARD)**

Prescription Only Medicine

**8. SPONSOR**

Pfizer Australia Pty Ltd  
Level 17, 151 Clarence Street  
Sydney NSW 2000  
Toll Free Number: 1800 675 229  
www.pfizer.com.au

**9. DATE OF FIRST APPROVAL**

4 June 2008

**10. DATE OF REVISION**

27 March 2020

® Registered Trademark

### Summary Table of Changes

| Section changed | Summary of new information                          |
|-----------------|---|
| All             | All sections reformatted in line with the new form. |
| 1; 2; 3; 4; & 6 | Editorial   |
| 3               | Diluent dose form added                             |
| 8               | Sponsor details updated                             |